This procedural win removes near-term dismissal risk for Humana's antitrust claims, but the case is still in early discovery with no damages quantified. Monitor for summary judgment motions and any settlement developments in the broader MDL, which could take years to resolve. The stock impact is likely modest given the early stage and lack of financial specifics.
Price Chart
Executive Summary
In the long-running Generic Pharmaceuticals MDL antitrust litigation, Judge Rufe ruled on Epic Pharma's motions to dismiss claims regarding Ursodiol price-fixing. Humana's complaint was among the eight that survived — the court found it sufficiently alleged Epic conspired with Lannett and Actavis to raise Ursodiol prices, including specific allegations of parallel price hikes (Epic raised price 1000% from $0.45 to $5.10 per unit days after Lannett entered the market at $5.11) and pre-collusion communications. This is a procedural win for Humana, keeping its antitrust claims alive, but no damages have been awarded and the case remains in early stages.
Court Ruling Details
Key Facts
- Humana's antitrust complaint against Epic Pharma regarding Ursodiol price-fixing survived a motion to dismiss (denied).
- The court found Humana's complaint plausibly alleged Epic conspired with Lannett and Actavis to fix Ursodiol prices, citing specific parallel price increases and pre-collusion communications.
- Epic raised Ursodiol price 1000% from $0.45 to $5.10 per 300-mg unit on May 6, 2014, days after Lannett entered the market at $5.11.
- Three other complaints (HCSC, Molina, CVS) were dismissed for failing to adequately plead Epic's involvement.
- No damages have been awarded; this is a procedural ruling allowing the case to proceed to discovery.
- The ruling is part of the broader Generic Pharmaceuticals MDL 2724, which has been ongoing since 2016.
Financial Impact
No damages awarded. The ruling allows Humana's antitrust claims to proceed to discovery. Potential recovery is not quantified in the document.
Risk Factors
- Case may still be dismissed at summary judgment if discovery fails to produce sufficient evidence of conspiracy.
- No damages amount has been specified; potential recovery may be small relative to Humana's $38.5B market cap.
- Appeals by Epic could delay proceedings further.
- The MDL has been ongoing since 2016 — resolution may take additional years.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion from CourtListener.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-lvpf066w-HUM |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 1, 2026 4w ago | 8-K | $394.45 $381.57 | ▼ −3.26% | ▼ −3.58% | $388.36 (−1.54%) |
Aug 17, 2026 6w ago | Institutional Cluster | $382.00 $384.72 | ▲ +0.71% | ▲ +2.02% | $388.36 (+1.66%) |
Aug 13, 2026 7w ago | Court Ruling | $384.97 $409.80 | ▲ +6.45% | ▲ +8.20% | $388.36 (+0.88%) |
Jul 29, 2026 9w ago | 8-K | $365.41 $391.06 | ▲ +7.02% | ▲ +2.00% | $388.36 (+6.28%) |
Jun 1, 2026 17w ago | 8-K | $328.31 $388.90 | ▲ +18.46% | ▲ +20.77% | $388.36 (+18.29%) |
Apr 10, 2026 25w ago | 8-K | $197.53 $274.15 | ▲ +38.79% | ▲ +31.06% | $388.36 (+96.61%) |
Mar 6, 2026 30w ago | DEFA14A | $179.09 $182.71 | ▲ +2.02% | ▲ +4.07% | $388.36 (+116.86%) |
Mar 2, 2026 30w ago | Court Ruling | $187.00 $166.00 | ▼ −11.23% | ▼ −3.29% | $388.36 (+107.68%) |
Mar 2, 2026 30w ago | Court Ruling | $187.00 $166.00 | ▼ −11.23% | ▼ −3.29% | $388.36 (+107.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access